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Abstract: An Henbest reduction, followed by the preparation f a silyl enol ether and oxidation i situ 
with m-CPBA has led to the neurosteroids 3cz-hydroxy- and 3(x,21-dihydroxy-Scvpregnanolones. Using 
testosterone as starting material, a new short synthesis of an aromatase inhibitor, 4-OHA, has been 
achieved through ydroboration/oxidation foll wed by a Swem type oxidation and epimerization. A other 
aromatase inhibitor, androst-4-ene-3,6,17-trione, has been efficiently prepared using PCC on 
montmorillonite KI0, under ultrasonic irradiation. ©1999 Elsevier Science Ltd. All rights reserved. 
INTRODUCTION 
Steroids are an important class of biologically active compounds and a large number are used in 
therapy.la,b Over the last 15 years the biochemistry of steroids has advanced very rapidly and such developments 
have been quite relevant for research of new drugs and led to a renewed interest in steroids. 
At present, potent and selective inhibitors of steroid-converting enzymes are very promising to use in 
association with steroid anti-hormones or as replacements. The inhibition of aromatase, a cytochrome P-450 
enzyme, 2 is of special interest in cancer therapy for two reasons. First the production of estrogens has been 
associated with breast cancer. Secondly, since the enzyme aromatase is involved in the final biosynthetic step, its 
inhibitors are of greater therapeutic interest) Further, inhibition of aromatase has been suggested tobe important 
in the treatment ofother malignant diseases in aging. 4
Recently researchers have provided a large body of evidence that supports the existence of a novel class of 
steroids which are devoid any known steroid hormone activity and have high specificity for the GABAA receptor 
complex (GRC), a iigand-gated chloride channel that mediates the inhibitory action of the neurotransmiter y- 
aminobutyric acid (GABA). 5 These neuroactive steroids have been termed epalons, a shortened form of 
epiallopregnanolone, and putative palon receptors may be unique sites on GRC that mediate the effects of 
neurosteroids on the GABA-gated channel function. Based upon some of the unique characteristics of epalons 
relative to barbiturates and benzodiazepines, it is plausible that they can be developed into a novel class of 
therapeutic agents for the treatment of anxiety, epilepsy and insomnia. 6 
From our recent research, we wish to contribute to new ways to improve efficiency and selectivity in 
oxidation-reduction processes directed towards the synthesis of bioactive steroids, namely neuroactive steroids as 
epiallopregnanolone a depiallotetrahydrodeoxycorticosterone (epiallotetrahydro-DOC) andaromatase inhibitors 
as 4-hydroxyandrost-4-ene-3,17-dione and androst-4-ene-3,6,17-trione. 
0040-4020/99/$ - see front matter © 1999 Elsevier Science Ltd. All fights reserved. 
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RESULTS AND DISCUSSION 
Neurosteroids 
Endogenously occurring neuroactive steroids, such as 3(x-hydroxy- and 3~2 l-dihydroxy-5ct-pregnan-20- 
one, commonly named epiallopregnanolone 2 and epiallotetrabydro-DOC 3, have been shown to allosterically 
regulate the GABAA receptor function. 5c 
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In an earlier eport, 7the 3c¢-hydroxy-5ct-pregnane moi ty in the endogeneous neuroactive steroids 2 and 3 
(Figure 1) was obtained in moderate yield (54%) using the Mitsunobu reaction to accomplish the inversion of 
configuration at C-3 on the common 313-hydroxy-5c~-pregnan-20-one. Subsequent 21-acetoxylation with lead 
tetraacetate (LTA), followed by hydrolysis under mild basic conditions led to the required (x-ketol group in 35% 
yield for epiallotetrahydro-DOC 3 (Figure 1). Therefore, the 21-hydroxylation is the most detrimental step to the 
overall yield of such synthetic route. 
Despite the relevant properties of the aforementioned steroids, there have been no efforts to improve their 
synthesis. As a part of our on-going research directed towards the chemical synthesis of steroidal metabolites 8 we 
have been investigating alternative methods to achieve the 2 l-oxidation. Consequently, the following improved 
synthetic route to epiailotetrahydro-DOC 3 was developed. 
The commercially available 5(x-pregnane-3,20-dione 1 was used as starting material (Scheme 1) and among 
the methods available to accomplish the reduction of the 3-oxo group we selected the Henbest reduction,9a,b, c 
owing to its stereo and chemoselectivity. Under these combined conditions,gb, c i.e. chloroiridie acid with aqueous 
isopropanol and hypophosphorous acid, we were able to obtain the 3~-axial alcohol 2 in 60 % yield after 
crystallization from n-heptane to remove the epimer with inverted stereochemistry at C-17 (12 %) found in the 
crude. The product obtained has showed a high degree of purity (95-97%). The 13-side chain at C-17 on 
compound 2 was ascertained by IH nmr (0.60 ppm for 18-H3 and 2.53 ppm for 17or-H) and 13C nmr (11.18 
ppm for C-18) spectra which were consistent with the published ata.10 Therefore, the use of hypophosphorous 
acid led to an improvement of such reductions, allowing yields that are almost he double of the previously 
reported for identical reactions using trimethyl phosphite (35%). 9b In a similar manner to that described above, 
5ct-androstane-3,17-dione a d 5~-eholestanone produced exclusively the corresponding 3(x-hydroxy 
compounds. 9dIt should be also emphasized that, in our hands, the Henbest reduction gave more reproducible 
results than the Mitsunobu reaction. 
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Scheme 1 Reagents and conditions: i, H21rCIs. 6H20, PrOH aq., HaPO 3 , r.t.; ii, TBDMSOTf, Et3N, CH2CI2, 5 °C; 
iii, m-CPBA, n-CsH12, -15 °C to r.t.; iv, conc. HCI : EtOH (2:98). 
Different approaches have been used to perform the oxygenation atC-21 on 20-oxosteroids.l I Although the 
reaction with LTA 12 is the most often used to indirectly provide this functionalization  steroids, the yields 
achieved are usually poor to moderate. The enolization of 20-oxosteroids has been investigated recently in our 
laboratory 13 and the results obtained led us to forecast the oxidation of a silyl enol ether derivative 14 as a readily 
conceivable alternative to the methods commonly used to introduce the 21-hydroxy group. Indeed, the 21- 
oxidation was efficiently accomplished in 71% yield using the conditions outlined in Scheme 1. Thus, treatment 
of 2 with the highly reactive t-butyldimethylsilyl triflate (TBDMSOTf) 13 led simultaneously tothe 20-ketone 
enolization and the 3¢¢-OH silylation. The progress of the enolization could be followed by IH nmr, monitoring 
the 2 l-H3 singlet at 2.11 ppm for compound 2. Subsequent oxidation in situ of 2a with m-chloroperbenzoic acid 
(m-CPBA) 14 followed by the spontaneous rearrangement of the unstable 20,21-epoxide smoothly afforded the 
corresponding silylated o~-ketol 2b from which target epiallotetrahydro-DOC 3 was prepared by hydrolytic 
cleavage of the silyl ether groups at C-3 and C-21 under mild acidic conditions. The structure of 3 was confirmed 
by spectroscopic data. Namely, an AB system was observed at 5I-I 4.20 ppm and 4.15 ppm for the two protons at 
C-21 and also the chemical shift for this carbon at ~c 69.3 ppm as well as for C-20 (8C 210.4 ppm) and C-3 (iSC 
66.4 ppm). The yield of the 2 l-hydroxy derivative achieved by this procedure (71%) is markedly superior to that 
obtained by LTA oxidation (35 %).7 Consequently, taking in account such result his oxidative process became a
method of choice to perform the 2 l-hydroxylation on 20-oxosteroids. 
The relative convenience ofthe silyl enol ether peroxidation with m-CPBA to achieve the oxidation at C-21 
has been reinforced by the application of the described procedure to obtain other important biologically active 
steroids. 15 
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Steroid Aromatase Inhibitors 
Among the steroid aromatase inhibitors, 4-hydroxyandrost-4-ene-3,17-dione (4-OHA) 10 (Figure 2), also 
called formestane, has proved to be very effective in the treatment of advanced breast cancer 16a,b and quite 
recently has found clinical use. 17 
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Figure 2 
Most of the syntheses reported rely upon acid- or base-catalysed opening of a mixture of 4a,5a- and 
4~,5~-epoxides obtained by treatment of androstenedione with alkaline H202, however the overall yields were 
generally low.18a,b,c More recently, amoderate yield was reported via alkaline dehydration of4,5-diois, obtained 
from androstenedione with osmium tetroxide in the presence of hydrogen peroxide. 19 
The establishment of 4-OHA as a drug and the recent upsurge on studies towards the elucidation of the 
active site of aromatase with 4-androstenedione analogs, 2o led us to explore alternative syntheses for this 
compound (10). Two new strategies have been depicted to circunvent the poor yields reported for the preparation 
of 4-OHA (Scheme 2). One of these, already reported, 21uses 5ct-androst-3-en-17-one 4 as starting material and 
through a two-step oxidative route followed by base-catalysed isomerization leads to 4-OHA, 10 (route A). 
We describe herewith another strategy (route B), which uses the readily available testosterone 6 as starting 
material. Under the hydroboration/oxidation c ditions described for cholest-4-en-3-one, 22 reduction at C-3 
preceeds the formation of the 3~,4a-dihydroxy moiety. When the reaction was quenched after 2 hours the 
intermediate compound 7 was the only compound isolated and the ailylic alcohol moiety was detected by IH nmr 
(4.14 ppm for 4-H and 5.28 ppm for 3cx-H) and 13C nmr (67.8 ppm for C-3 and 123.6 ppm for C-4 and 147.3 
ppm for C-5) spectra which were consistent with the published ata. 23a,b,c Further, using Swern type conditions, 
DMSO-trifluoroacetic anhydride, 3~,4o~,17~-triol 8 was quantitatively oxidized to afford the kinetic diosphenol 
3-hydroxy-5c~-androst-2-ene-4,17-dione 9 which by base-catalysed isomerization led to the desired 
thermodynamic d osphenol, 4-OHA 10 (Scheme 2). 
The reagents used in both short convergent routes are non-toxic and moderately inexpensive, and most of 
the reactions are fast and high yielding. Nevertheless, the low cost of the readily available starting material, 
testosterone 6, used in route B renders this approach very competitive toprepare 4-OHA. 
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Scheme 2 Reagents and conditions: i, H202, HCO2H, r.t., lh; i', BFa-etherate, NaBH4, Diglyme, THF, r.t., 
24h then H202, KOH, reflux, 5'; ii, DMSO, TFAA, -60 °C, 3h then Et3N, -60 °C 15'; iJi, Na, MeOH, r.t., lh. 
Another aromatase inhibitor, the androst-4-ene-3,6,17-trione 12 (Figure 3) is an important A4-3,6-dioxosteroid 
with general biological interest. 24 Most of the processes mentioned in the literature used Cr(vI) reagents under 
drastic conditions to oxidize AS-3[i-hydroxy groups. 2s Some years ago we developed a mild method for this 
transformation with tetra-n-propylammonium perruthenate (TPAP) and 4-methylmorpholine N-oxide as co- 
oxidant under ultrasonic irradiation. 26 However the considerable expense of using TPAP led us to search for 
other processes. Recently, the use of the milder pyridinium chlorochromate (PCC) to perform this type of 
transformations has been reported, although large amounts of the reagent are required. 27 
O 12 
Figure 3 
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The use of ultrasound in organic reactions has been widely applied in synthesis 28 and our previous 
experience 29encouraged us to utilize this technology in our process. Moreover, the use of PCC on clays under 
ultrasonic irradiation allowed us to benefit from the use of supported reagents, especially to afford products free 
from contamination with by-products.30 
When the dehydroepiandrosterone 11 was treated with 4 mmoles of PCC on montmorillonite KI0 under 
sonochemical conditions, a fast reaction led to the aromatase inhibitor androst-4-ene-3,6,17-trione 12, in high 
yield (Scheme 3 and Table I). 
PCC/solid support . 
HO Oioxane ))) 0 
0 
11 12 
Scheme 3 
Table 1. Oxidation of Dehydroepiandrosterone with PCC on montmorillonite K 10 
Entries PCC a Solid Product Yield b 
mmoles support (%) 
1 4 K 10 12 + AS-3-ketone <20 
2 4 - -  / ))) 1 2 86 
3 4 K10/)))  12 
aThe reactions were performed with 1 mmole of substrate, bReaetion time 45 minutes. 
90 
The effect of ultrasonic irradiation on the reaction performed allows us to conclude that ultrasound promotes 
a drastic reduction on the amount of PCC used when compared with similar transformations previously 
reported. 27In addition, apositive ffect on the rate and the yield of the reaction has been observed (Entries 2 and 
3,Table 1). Furthermore, the use of solid supports gives an easier work-up. Under the described conditions, 
similar esults have been found for pregnenolone and cholesterol, allowing the synthesis of the corresponding A 4- 
3,6-dioxosteroids with improved efficiency. 
In summary, a new methodology has allowed a significant improvement for each one of the reactions 
sequence l ading to the 3¢t- and 2 l-hydroxylations required to synthesize the neurosteroids epiallopregnanolone 2 
and epiallotetrahydro-DOC 3. The Henbest reduction of the C-3 unhindered ketone is reproducible and the 
preparation of a silyl enol ether, and its oxidation in situ with m-CPBA have allowed the 2 l-hydroxylation i
better overall yield. Moreover, a new short synthesis of the aromatase inhibitor, 4-OHA 10, has been achieved 
with the advantage ofusing testosterone 6 as a low cost starting material, besides most of the reactions being high 
yielding. In addition, the combination of ultrasound with clay supported PCC has been shown to be very 
beneficial in terms of reaction rate, reagent economy and work-up simplification to prepare the aromatase 
inhibitor, androst-4-ene-3,6,17-trione 12. 
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EXPERIMENTAL SECTION 
5a-Pregnane-3,20-dione a d dehydroepiandrosterone were commercially available from Sigma and 
testosterone from Steroid Cologno Monzese. TBDMSOTf (98%) and m-CPBA (80-90%) were commercially 
obtained from Aldrich Chemic. Reaction solvents were dried and distilled before use according to standard 
procedures. Melting points were determined with a Reichert microscope apparatus and were uncorrected. Unless 
otherwise stated i.r. spectra refer to KBr pellets. 1H nmr and 13C nmr were performed in CDCI3, unless 
otherwise indicated, with Me4Si as internal standard. J values are given in Hz. For TLC analyses Kieselgel 60 
HF254/kieselgel 60 G was used. The Henbest reduction was performed according to the conditions reported in the 
literature.9b, c 
General Procedure for 21-Hydroxylation" 3a-Hydroxy-20-oxopregnane 2 (250 mg, 0.785 retool) 
was dissolved in CH2CI2 (2 ml). This solution was stirred at room temperature and then triethylamine (2.0 ml) 
immediately followed by TBDMSOTf (2 ml, 8.53 retool) were added dropwise. 13 The reaction was followed by 
1H nmr recording the spectra between 1.5 and 2.5 ppm. After 1 hour the 21-H3 singlet, at 2.11 ppm, of the 
starting material 2 was absent. Subsequently, the reaction mixture was diluted with CH2C12 (20 ml), extracted 
with 10% NaHCO3 (2x10 ml) and the organic phase was dried over anhydrous MgSO4. Filtration and removal of 
the solvent under reduced pressure afforded the crude product which was dissolved in anhydrous ether. 
Subsequent tofiltration and evaporation of the solvent under educed pressure, the 20-(t-butyidimethylsilyl)oxy- 
3a-hydroxypregn-20-ene 2a was obtained. A solution of this enol silyl ether 2a in n-hexane (7.0 ml) was added 
dropwise to a suspension of m-CPBA (260 mg, 1.28 mmol) in n-hexane (20 ml) at -15 0C, under magnetic 
stirring. The mixture was kept at -15 0C for 10 min and then was allowed to warm up to room temperature. The 
reaction was followed by TLC (ether/toluene, 2:8). After 4 hours the solvent was evaporated under reduced 
pressure. The solid obtained was dissolved in pentane and the residual m-CPBA, insoluble in this solvent, was 
removed by filtration. The filtrate was washed with 10% NaHCO3 (3x25 mi) and H20 (3x25 ml) and the organic 
phase was dried over anhydrous MgSO4. The crude obtained (530 mg) by evaporation of the solvent under 
reduced pressure was immediatly dissolved in a 2% cone. HC! / EtOH solution (20 ml) and the reaction was 
stirred at room temperature for 24 hours. Then was diluted with cold H20, neutralized with 10% Na!-ICO 3 and 
extracted with CH2Ci2 (3x150 ml). The organic phase was successively washed with 10% NaHCO3 (3x150 mL) 
and H20 (2x100 ml) and dried over anhydrous MgSO4. Evaporation of the solvent under reduced pressure 
afforded, after crystallization, the 3¢~,21-dihydroxy-20-oxopregnane 3 (185 rag, 71%): nap 165°C (acetone / 
ethanol), [lit. 31 163-166 °C (acetone)]; Vmax 3350 (OH), 1710 (CO), 1375 cm-l; 1H nmr (500 MHz) 8 0.63 (3H, 
s, 18-H3), 0.78 (3H, s, 19-H3), 2.45 (1H, t, J9 ,  17c¢-H), 4.05 (1H, t, J 2.5, 3[3-H), 4.18 (2H, qAB, 5A=4.20, 
~B =4.15, JAB 18.5, 21-H2); 13C NMR 5 11.13 (C-18), 13.5 (C-19), 66.4 (C-3), 69.3 (C-21), 210.4 (C-20); 
M + (EI) 334.493. 
Synthesis of 5~-androstane-3[3,4o¢,l 7[3-triol 8 
A stirred solution of testosterone 6 (500 rag; 1.73 mmol) in dry tetrahydrofuran (17 ml) was treated with an excess 
of diborane at 0 °C under dry nitrogen for 6 h. The gas was generated externally 32 by slow dropwise addition of a 
0.2M solution of sodium borohydride in diglyme (31.2 ml) to a cool (0 °C) and stirred boron trifluoride therate- 
diglyme solution (I .2 ml; 12.74 mmol) and then passed into the steroid-tetrahydrofuran solution by applying a 
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slight flow of dry nitrogen through the generator. The generator was then disconnected from the hydroboration 
flask, the temperature was raised to 20 °C and the solution was stirred for a further 18 h (TLC control) after which 
the mixture was carefully diluted with water (10 ml). Potassium hydroxide (5% methanol solution; 7 ml) was then 
added to the mixture followed by dropwise addition of hydrogen peroxide (30%; 1.3 ml) and the mixture was 
heated under eflux for 5 min. The solution was neutralized with a 10% aq. HCI, poured into stirred cold water (75 
ml) and the insoluble solid was filtered and dried to yield the pure title compound 8 (231 rag; 43%). The aqueous 
phase was further extracted with diehloromethane, the extract was washed with aq. NaHCO3 and water, dried 
(MgSO4) and evaporated todryness to give a solid residue which after trituration with ethyl acetate followed by 
filtration yielded an additional portion (67 mg; 12 %) of the pure compound 833a,b,c,d, ~H(500 MHz; PYd6) 0.90 
(3H, s, 18-H3), 0.99 (3H, s, 19-H3), 3.70 (IH, dd, J 17a,16a 9-2, J 17c~,161~ 9.2, 17¢Z-H), 3.82 (1H, ddd, J 3¢~,2[~ 
1 1.6, J 3a,413 8.6, J 3¢x,20~ 5.2, 3¢x-H), 3.90 (1H, dd, J 41~.5c, 8.6, J 4l~,3cx 8.6, 4[3-H), 5.01-6.05 (3H, 3-OH, 4-OH 
and 17-OH, disappeared with D20); 5¢(125 MHz, PYd6) 11.9(C-18), 13.9(C-19), 75.534(C-3), 76.734(C-4), 
81.4 (C- 17). 
Synthesis of 3-Hydroxy-Sc~-androst-2-ene-4,17-dione 9 
To a stirred and cooled (-60 °C) mixture of dimethylsulfoxide (0.23 ml; 3.24 retool) in dichloromethane (9 ml) 
under nitrogen, trifluoroacetic anhydride (0.41 ml; 2.95 retool) was added ropwise. After 10 rain a solution of 
the triol 8 (155 rag; 0.50 mmoles) in a mixture of dichloromethane and dimethylsulfoxide (2 ml) was added and 
stirred until the steroid was consumed (3h, TLC control). Triethylamine (1.0 ml; 7.17 mmol) was then added and 
after 15 rain. at -60 oC the temperature was raised to 5 °C. The solution was poured into 2N hydrochloric acid (40 
ml) and extracted with dichloromethane. The extract was washed with aq. NaHCO3 and water, dried (MgSO4) 
and evaporated todryness yielding the crude diosphenol 921 (149 mg; 98%) as the only detected product. This 
pale yellow solid could not be crystallized, 35and an analytical sample was purified by column chromatography 
[silica gel; ethyl acetate-light petroleum (bp 60-80 °C) (1:1)]; (Found: C, 75.46; H, 8.97. C19H2603 requires 
C,75.46; H, 8.67%); Vmax 3400 (OH), 1743 (C--O), 1675 cm -1 (C--O); 5H(500 MHz) 0.88 (3FL s, 18-H3), 0.93 
(3H, s, 19-H3), 5.85 (1H, s, 3-OH, disappeared with D20), 5.96 (IH, dd, JzA 3.0, J2,1 7.0, 2-H); 8c(50.3 
MHz) 13.2 (C-18), 13.7 (C-19), 113.9 (C-2), 145.9 (C-3), 196.8 (C-4) 220.7 (C-17). 
Synthesis of 4.Hydroxyandrost-4-ene-3,17-dione 10 
To a stirred and cooled (0 °C) solution of 9 (60 rag; 0.2 retool) in methanol (3 ml) under nitrogen, sodium metal 
(50 rag; 2.2 retool) was added. After lh at room temperature the solution was neutralized with 10% aq. HCI and 
the usual work-up was followed. The residue was purified by flash chromatography [silica gel; diethyl ether- 
cation tetrachloride (1:1)] to give the title compound 10 (48 rag, 80%) as pure colourless needles, nap 202-203 
°C (ethyl acetate) [lit. 18c 201-2030C]; Vmax 3415, 3390 (OH), 1743 (C=O), 1672 (C=O), 1636 cm "1 (C=C); 
8H(500 MHz) 0.92 (3H, s, 18-H3), 1.20 (3H, s, 19-H3), 3.069 (1H, m, 6a-H), 6.16 (1H, s, 4-OH, 
disappeared with D20); 8c(125 MHz) 13.7 (C-18), 17.1 (C-19), 139.2 (C-5), 141.3 (C-4), 193.5 (C-3) 220.7 
(C-17). 
General Procedure for A4-3,6-diketones 
PCC (860mg; 4 mmoles) and montmorillonite KI0 (500rag) were ground into a fine powder and the mixture was 
added to a flask containing DHA 11 (288,4mg; lmmole) in dioxane (20ml). The mixture was submitted to 
ultrasonic irradiation with an immersion probe system (Sonics& Materials Inc, Mod. V.C. 600W, 20KHz, 1/2 
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inch probe 80Wcm-2) and after 45 minutes, TLC analysis (1:1, EtOAc/petroleum ether 40-60°C) indicated the full 
conversion of AS-3[5-hydroxy steroid into A4-3,6-diketone. The reaction solution was diluted with Et20 and 
filtered through Celite. Excess solvent was removed under educed pressure to afford a yellow oil which was 
chromatographed on silica gel, 70-230 mesh, (1: !, EtOAc/petroleum ether 40-60"C). The organic phase was then 
sucessively washed with 10% aqueous odium bicarbonate (2x50ml),water (2xl00ml), and dried (Na2SO4). 
Removal of the drying agent and solvent resulted in a solid which after crystallization (isopropyl ether) gave the 
product 1225b,26 (367mg; 89%). mp 220-222°C (isopropyl ether) [lit. 25b 222-227°C], Vma x 2956, 1737, 1686, 
1600 (C=C), cm'l.SH(300 MHz) 0.87 (3H, s, 18-H3), 1.14 (3H, s, 19-H3), 6,13 (l-H, s, 4-H). 8c(75 MHz) 
125.75 (C-4), 160.05 (C-5), 198.95 (C-3), 201.02 (C-6), 219.09 (C-17). 
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